Simcere Pharmaceutical Group Limited

HKSE 2096.HK

Simcere Pharmaceutical Group Limited Return on Equity (ROE) for the year ending December 31, 2023: 9.90%

Simcere Pharmaceutical Group Limited Return on Equity (ROE) is 9.90% for the year ending December 31, 2023, a -24.24% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Simcere Pharmaceutical Group Limited Return on Equity (ROE) for the year ending December 31, 2022 was 13.06%, a -44.21% change year over year.
Simcere Pharmaceutical Group Limited Return on Equity (ROE) for the year ending December 31, 2021 was 23.41%, a 85.40% change year over year.
Simcere Pharmaceutical Group Limited Return on Equity (ROE) for the year ending December 31, 2020 was 12.63%, a -81.37% change year over year.
Simcere Pharmaceutical Group Limited Return on Equity (ROE) for the year ending December 31, 2019 was 67.79%, a 44.62% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

HKSE: 2096.HK

Simcere Pharmaceutical Group Limited

CEO	Mr. Jinsheng Ren
IPO Date	Oct. 27, 2020
Location	China
Headquarters	No. 699-18, Xuanwu Road
Employees	6,412
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.

Key trends

Past 5 years